

Status (Multiple Items)

Drug Name	Tumour Group	Regimen Name on NCCP website	Regimen Number
5-Fluorouracil	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
		CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734
	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
		5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)-Continuous infusion 7 day	421
		Aflibercept-14 days	238
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		CISplatin 75mg/m2 and 5-Fluorouracil Chemoradiation Therapy-Herskovic Regimen	460
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429
		FLOT Therapy-14 day	344
		FLOX Therapy	486
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOX-4 Therapy-14 day	210
		FOLFOXIRI Therapy	555
		Modified FOLFIRINOX Therapy	515
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509
		Modified FOLFOX-6 Therapy-14 day	209
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594
		Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen	427
		5-Fluorouracil and Folinic Acid Therapy-14 day	660
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
		Cetuximab and FOLFOX-4 Therapy	692
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
		Cetuximab and FOLFOX-6 (modified) Therapy	733

5-Fluorouracil	Gastrointestinal	Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	739	
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	816	
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	832	
		Pembrolizumab and FOLFOX-6 Modified Therapy	839	
		Nivolumab and FOLFOX-6 Modified Therapy	844	
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Bevacizumab 5mg/kg, 5-Fluorouracil and Folinic Acid Therapy-14 dayi	791	
		Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
			CARBOplatin (AUC 5) and 5-Fluorouracil	
	Head & Neck	1000mg/m2/day Therapy – 28 day cycle	552	
		Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle	418	
		Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/day Therapy- 21 day cycle	417	
		CISplatin and 5-Fluorouracil Therapy-28 day	314	
		DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324	
		DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323	
		CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy	589	
		CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy	591	
		Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705	
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706	
DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)	315			
Abemaciclib	Breast	Abemaciclib Therapy	619	
Abiraterone	Genitourinary	Abiraterone 1000mg and Prednisolone 5mg Therapy	577	
		Abiraterone and Prednisolone Therapy	103	
Acalabrutinib	Leukaemia	Acalabrutinib (Tablets) Monotherapy	840	
Afatinib	Lung	Afatinib Monotherapy	221	
Aflibercept	Gastrointestinal	Aflibercept-14 days	238	
Alectinib	Lung	Alectinib Monotherapy	401	
Alemtuzumab	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611	
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625	
		Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638	
Anastrozole	Breast	Anastrozole Monotherapy	254	
Apalutamide	Genitourinary	Apalutamide therapy	574	
Arsenic trioxide	Leukaemia	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357	
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356	
Asciminib	Leukaemia	Asciminib Monotherapy	847	
Atezolizumab	Breast	Atezolizumab and nab-PAClitaxel Therapy	688	
	Gastrointestinal	Atezolizumab and Bevacizumab Therapy	831	
	Genitourinary	Atezolizumab 1680mg Monotherapy – 28 Day	593	

Atezolizumab	Genitourinary	Atezolizumab Monotherapy-14 day	592
		Atezolizumab Monotherapy – 21 Day	544
	Lung	Atezolizumab 1680mg Monotherapy – 28 Day	593
		Atezolizumab Monotherapy-14 day	592
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689
	Lung	Atezolizumab Monotherapy – 21 Day	544
		Atezolizumab 1680mg Monotherapy – 28 Day	593
		Atezolizumab Monotherapy – 21 Day	544
Atezolizumab SC	Genitourinary	Atezolizumab Monotherapy – 21 Day	544
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689
	Lung	Atezolizumab Monotherapy – 21 Day	544
		Atezolizumab Monotherapy – 21 Day	544
Avelumab	Skin/Melanoma	Avelumab Monotherapy	535
Axicabtagene ciloleu	Lymphoma (CAR-T)	Axicabtagene ciloleu (Yescarta®) (CAR-T) DLBCL and PMBCL	717
Axitinib	Genitourinary	Axitinib Monotherapy	104
		Pembrolizumab 200mg and Axitinib Therapy	583
Azacitidine	Leukaemia	Azacitidine 100mg/m2 5-day Therapy	288
		Azacitidine 75mg/m2 5-2-2 Therapy	287
Azacitidine	Leukaemia	azaCITIDine (Oral) Monotherapy	818
	Luekaemia	Venetoclax and azaCITIDine Therapy	852
Bendamustine	Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529
		Obinutuzumab and Bendamustine Therapy-28 day cycle	424
		riTUXimab and Bendamustine Therapy	345
		Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685
	Leukaemia	Bendamustine Monotherapy	527
Bevacizumab	Breast	Bevacizumab 10mg/kg-14days	212
		Bevacizumab 15mg/kg - 21 days	215
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy	738
	Gastrointestinal	Bevacizumab 10mg/kg-14days	212
		Bevacizumab 15mg/kg - 21 days	215
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Bevacizumab 7.5mg/kg-21days	214
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	
		Therapy- 21 day	623
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	623
		Atezolizumab and Bevacizumab Therapy	831
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446
	Bevacizumab 5mg/kg, 5-Fluorouracil and Folinic Acid Therapy-14 dayi	791	
	Genitourinary	Bevacizumab 10mg/kg-14days	212
		Gynaecology	Bevacizumab 10mg/kg-14days
			Bevacizumab 15mg/kg - 21 days
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499

Bevacizumab	Gynaecology	Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620	
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716	
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766	
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22) Therapy	769	
		Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy	771	
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy	799	
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811	
		Olaparib (Tablet) and Bevacizumab Therapy	746	
		Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy	772	
		Lung	Bevacizumab 15mg/kg - 21 days	215
			Bevacizumab 7.5mg/kg-21days	214
		Neuro-oncology	Lomustine and Bevacizumab 5mg/kg Therapy	742
			Lomustine and Bevacizumab 7.5mg/kg Therapy	804
Bevacizumab 5mg/kg Monotherapy – 14 Day	813			
Bicalutamide	Genitourinary	Bicalutamide Therapy	482	
binimetinib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563	
Bleomycin	Lymphoma	ABVD Therapy	290	
		Escalated Dose BEACOPP 21 day Therapy	354	
	Genitourinary/Gyr	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
Bleomycin	Lymphoma	Escalated Dose BEACOPDAC 21 Day Therapy	837	
Blinatumomab	Paediatric Oncology	Blinatumomab Paediatric Therapy	P00567	
		Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy	P00707	
	Leukaemia	Blinatumomab Therapy	538	
		Blinatumomab Therapy (ALL with MRD>0.1%)	590	
Bortezomib	Myeloma	Bortezomib , Melphalan and Prednisolone	275	
		Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274	
		Bortezomib and Dexamethasone Therapy	270	
		Bortezomib Maintenance Therapy- 14 day	435	
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416	
		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299	
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy	273	
		Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601	
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day	643	
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703	

Bortezomib	Myeloma	Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755	
			756	
		Bortezomib,Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy	780	
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781	
		AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28-Day Therapy	652	
	Myeloma	Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) Therapy	779	
bortezomib	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy	560	
		Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy	609	
		Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy	695	
		Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496	
Bosutinib	Leukaemia	Bosutinib Monotherapy	224	
Brentuximab vedotin	Lymphoma	Brentuximab vedotin and Bendamustine Therapy	529	
		Brentuximab vedotin Monotherapy	234	
		Brentuximab vedotin and ICE Therapy	528	
		Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) Therapy	801	
		Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)	530	
	Leukaemia	Brentuximab vedotin Monotherapy	234	
	Lymphoma	Brentuximab vedotin Monotherapy	234	
Brigatinib	Lung	Brigatinib Therapy	562	
Busulfan	Transplant	Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635	
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636	
		Busulfan/Cyclophosphamide MAC-MUD	639	
		Busulfan/Cyclophosphamide MAC-SIB	641	
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor	662	
		Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor	663	
Cabazitaxel	Genitourinary	Cabazitaxel and Prednisolone	101	
Cabozantinib	Genitourinary	Cabozantinib Therapy	518	
Capecitabine	Breast	Capecitabine Monotherapy	216	
		Lapatinib and Capecitabine	217	
	Gastrointestinal	Capecitabine 825mg/m2 and RT–7 day	586	
		Capecitabine and RT – 7 day	523	
		Capecitabine and Temozolomide Therapy*	505	
		Capecitabine Monotherapy	216	
		Capecitabine/Oxaliplatin (XELOX) Therapy	321	
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473	
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380	
epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239			

Capecitabine	Gastrointestinal	Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524	
		Gemcitabine + Capecitabine Therapy	384	
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day		
		Therapy- 21 day	623	
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691	
		mitoMYcin and Capecitabine Chemoradiation Therapy	727	
		Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day	623	
		Nivolumab and XELOX Therapy	843	
CARBOplatin	Breast	CARBOplatin (AUC4-6) Monotherapy-21 days	261	
		CARBOplatin (AUC4-6) Monotherapy-28 days	251	
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348	
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258	
		Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430	
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722	
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731	
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775	
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789	
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790	
		CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734	
		Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860	
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861	
		Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857	
			858	
		Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	422
		Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453
			Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
			TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
Gynaecology	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419		
	CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308		
	CARBOplatin (AUC4-6) Monotherapy-21 days	261		

CARBOplatin	Gynaecology	CARBOplatin (AUC4-6) Monotherapy-28 days	251	
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499	
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620	
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676	
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716	
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766	
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811	
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817	
		Head & Neck	CARBOplatin (AUC 2) Weekly with Radiotherapy (RT)	419
			CARBOplatin (AUC4-6) Monotherapy-21 days	261
			CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days	332
	CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m2/day Therapy – 28 day cycle		552	
	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m2/day Therapy - 21 day cycle		418	
	CARBOplatin 70mg/m2 and 5-Fluorouracil 600mg/m2 with Radiotherapy		589	
	CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m2 with Radiotherapy		591	
	Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy		705	
	Lung		CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561
			CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271
		CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy	304	
		CARBOplatin and Oral Etoposide Therapy-21 days	319	
		Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579	
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568	
		PEMEtrexed and CARBOplatin Therapy	318	
		Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy	309	
		CARBOplatin and vinORELbine Therapy-21 Day	614	
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689	
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy		712		
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy		713		

CARBOplatin	Lymphoma	(R**) -ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		Brentuximab vedotin and ICE Therapy	528
		ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842
	Lymphoma	(R*) -ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751
Carfilzomib	Myeloma	Carfilzomib (56mg/m <sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (20/70mg/m <sup>2</sup> Once weekly) Dexamethasone (Kd) therapy - 28 day	595
Carfilzomib	Myeloma	Carfilzomib and Dexamethasone (Kd) Therapy - 28 day	566
		Carfilzomib (27mg/m <sup>2</sup> twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
Carmustine	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638
Carmustine (BCNU)	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
Cemiplimab	Gynaecology	Cemiplimab Therapy	812
	Skin/Melanoma	Cemiplimab Therapy	812
Ceritinib	Lung	Ceritinib Monotherapy	340
Cetuximab	Gastrointestinal	Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		Cetuximab Monotherapy-7 days	207
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		Cetuximab and FOLFOX-4 Therapy	692
		Cetuximab Therapy-14 days	732
		Cetuximab and FOLFOX-6 (modified) Therapy	733
	Head & Neck	Cetuximab (weekly), CARBOplatin AUC 5 and 5-FU 1000mg/m <sup>2</sup> /day Therapy - 21 day cycle	418
		Cetuximab (weekly), CISplatin 100mg/m <sup>2</sup> and 5-FU 1000mg/m <sup>2</sup> /day Therapy- 21 day cycle	417
Cetuximab Monotherapy-7 days		207	
Chlorambucil	Lymphoma	Chlorambucil 10mg/m <sup>2</sup> Therapy	411
	Leukaemia	Chlorambucil 10mg/m <sup>2</sup> Therapy	411
		Obinutuzumab and Chlorambucil Therapy	286
CISplatin	Gastrointestinal	CISplatin 75mg/m <sup>2</sup> and 5-Fluorouracil Chemoradiation Therapy- Herskovic Regimen	460
		CISplatin and Capecitabine Adjuvant Chemoradiation Therapy	473
		CISplatin and Teysuno-28 day cycle	235
		epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380
		Gemcitabine (1000mg/m <sup>2</sup> ) and CISplatin (25mg/m <sup>2</sup> ) Therapy- 21 day	383
		Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502
		CISplatin, Infusional 5-Fluorouracil and Radiation Therapy	594
		Pembrolizumab 200mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusional Therapy	739
		Nivolumab 240mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusional Therapy	816
		Nivolumab 480mg, CISplatin 80mg/m <sup>2</sup> and 5-Fluorouracil Infusional Therapy	832
	Genitourinary	CISplatin (40mg/m <sup>2</sup> ) Weekly with Radiotherapy (RT)	385



CISplatin	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337	
		Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day	282	
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333	
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338	
		Gemcitabine (1000mg/m2 ) and CISplatin (35mg/m2 ) Therapy- 21 day	622	
		Gemcitabine (1000mg/m2 ) and CISplatin (70mg/m2 ) Therapy- 21 day	628	
		PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy	602	
	Gynaecology	CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385	
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266	
		Two Day Etoposide CISplatin (EP) Therapy	267	
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264	
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676	
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy	799	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279	
		Head & Neck	Cetuximab (weekly), CISplatin 100mg/m2 and 5-FU 1000mg/m2/ day Therapy- 21 day cycle	417
			CISplatin (100mg/m2) with Radiotherapy (RT)	387
			CISplatin (40mg/m2) Weekly with Radiotherapy (RT)	385
	CISplatin and 5-Fluorouracil Therapy-28 day		314	
	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy		324	
	DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy		323	
	Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day		517	
	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day		615	
	Pembrolizumab, CISplatin and 5-Fluorouracil Therapy		706	
	DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)		315	
	Lung	CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456	
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280	
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	281	
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569	
		PEMEtrexed and CISplatin Therapy	317	
		Vinorelbine and CISplatin Therapy-21 days	339	
		Vinorelbine and CISplatin Therapy-28 days	343	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279	
		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714	

CISplatin	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463	
		DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	420	
	Neuro-oncology	CISplatin, Lomustine and vinCRISTine (CLV) Therapy	806	
	Lymphoma	(R**)-DHAP Therapy	395	
		(R*)- ESHAP Therapy	394	
		riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441	
		ESHAP Therapy	838	
	Myeloma	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496	
		Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300
			Etoposide and CISplatin 20mg/m2 (EP) Therapy	301
Cladribine	Leukaemia	Cladribine 0.14mg/kg Day 1 to 5 Therapy	402	
		Cladribine 0.14mg/kg Weekly Therapy	469	
	Leukaemia, Lymph	Cladribine 5 day and riTUXimab Therapy	531	
		Cladribine Weekly and riTUXimab Therapy	534	
Cobimetinib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373	
Crizotinib	Lung	Crizotinib Monotherapy	243	
cycloPHOSphamide	Myeloma	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496	
cycloPHOSphamide	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265	
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269	
		CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381	
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378	
		DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485	
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316	
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433	
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252	
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260	

cycloPHOSphamide	Breast	DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734
		Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
		Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857
			858
			248
	Gynaecology	EMA/CO Therapy	248
	Head & Neck	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615
	Sarcoma	Etoposide and ifosfamide - vinCRiStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
			747
	Lymphoma	(*riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRiStine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*riTUXimab), Cyclophosphamide VinCRiStine and Prednisolone (*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**)- miniCHOP Therapy – 21 days	436
		CHOEP Therapy– 21 days	396
		Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Cyclophosphamide, DOXOrubicin, vinCRiStine and prednisoLONE (CHOP) Therapy– 21 days	841
riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRiStine and Prednisolone (R-CHOP) Therapy– 21 Days		667	
Dose Adjusted R (S/C)-EPOCH Therapy		672	
(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRiStine and PrednisoLONE (*R)-GCVP) Therapy–21 days		737	
Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) Therapy		801	

cycloPHOSphamide	Lymphoma	Polatuzumab Vedotin, ritUXImab, cycloPHOSphamide, DOXOrubicin and prednisoLONE Therapy	833
		Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISTine and prednisoLONE (O-CHOP) Therapy – 21 day	549
	Myeloma	Obinutuzumab cycloPHOSphamide vinCRISTine and prednisoLONE (O-CVP) Therapy – 21 day	550
		Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone –Weekly Therapy	299
		Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day Therapy	273
	Lymphoma and M	AL Amyloidosis: cycloPHOSphamide, Bortezomib and dexAMETHasone (CVD) 28-Day Therapy	652
		Cyclophosphamide 2000mg/m2 For Stem Cell Mobilisation	438
	Leukaemia	Fludarabine, Cyclophosphamide and ritUXImab (FC IV+R) Therapy	241
	Lymphoma, Myelo	cycloPHOSphamide 1500mg/m2 For Stem Cell Mobilisation	795
	Lymphoma	Escalated Dose BEACOPDAC 21 Day Therapy	837
	Lymphoma (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL	606
		Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)	608
	Leukaemia (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL	607
		Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor		630
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD		631
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB		637
	Busulfan/Cyclophosphamide MAC-MUD		639
	Busulfan/Cyclophosphamide MAC-SIB		641
	Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor		662
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor	663		
Myeloma	Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) Therapy		779
Cyclophosphamide - Oral	Breast		Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy
	Lymphoma	Dexamethasone, ritUXImab and Cyclophosphamide (DRC)Therapy	532
	Leukaemia	Fludarabine, Cyclophosphamide and ritUXImab (FC Oral+R) Therapy	410
Cytarabine	Lymphoma	(R**)-DHAP Therapy	395
		BEAM Autologous Transplant Conditioning Protocol	408
		High dose Methotrexate, high dose cytarabine, ritUXImab and thiotepa (MATRix) therapy	508
		LEAM Autologous Transplant Conditioning Protocol	468
		Nordic Therapy	393
		R-IVAC Therapy (Patients greater than 65 years)	404

Cytarabine	Lymphoma	R-IVAC Therapy (Patients less than or equal to 65 years)	399
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		(R*)- ESHAP Therapy	394
		High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy	666
		ESHAP Therapy	838
		Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)	530
	Leukaemia	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		FLAG:Ida 8mg/m2 Therapy	362
		High Dose Cytarabine Therapy	365
		Intermediate Dose Cytarabine Therapy	364
		FLAG Therapy	363
		Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
	Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy	683	
Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638	
Dabrafenib	Skin/Melanoma	Dabrafenib Monotherapy	237
		Trametinib and Dabrafenib Therapy	415
Dacarbazine	Sarcoma	Dacarbazine (1.2 g/m2) Therapy – 21 day	511
	Skin/Melanoma	Dacarbazine Therapy	464
	Lymphoma	ABVD Therapy	290
	Lymphoma	Escalated Dose BEACOPDAC 21 Day Therapy	837
Dacomitinib	Lung	Dacomitinib Monotherapy	565
DACTINomycin	Gynaecology	DACTINomycin Therapy	247
		EMA/CO Therapy	248
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264
	Sarcoma	Ifosfamide, vinCRIStine, DOXOrubicin, DACTINomycin (IVADo) Therapy	754
Darolutamide	Genitourinary	Darolutamide Therapy	693
Daratumumab	Myeloma	Daratumumab (IV), bortezomib and dexamethasone therapy	560
Daratumumab	Myeloma	Daratumumab Monotherapy	426
Daratumumab SC	Myeloma	Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy	609
		Daratumumab SC Monotherapy	604
		Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy	695
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
	Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755	
		756	
Myeloma	Daratumumab, Bortezomib, cycloPHOSphamide and dexAMETHasone (D-VCd) Therapy	779	

Daratumumab SC	Myeloma	Daratumumab SC, lenalidomide and dexamethasone therapy	854
Daunorubicin	Leukaemia	DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)	360
		DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)	359
		Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
Decitabine	Leukaemia	Decitabine Monotherapy – AML (28 day cycle)	231
Degarelix	Genitourinary	Degarelix Therapy- 28 day	481
Denosumab	Breast, Genitourin	Denosumab 120mg Therapy	741
Dinutuximab beta	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy	P00548
DOCEtaxel	Breast	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	250
		DOCEtaxel Monotherapy 100mg/m <sup>2</sup> – 21 day cycle	202
		DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
		DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258
		DOXOrubicin 50mg/m <sup>2</sup> /DOCEtaxel 75mg/m <sup>2</sup> (AT 50/75) Therapy - 21 day cycle	423
		Pertuzumab + Trastuzumab + DOCEtaxel	204
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731
		DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789
		Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle	796
	Gastrointestinal	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
		FLOT Therapy-14 day	344
	Genitourinary	DOCEtaxel 75mg/m <sup>2</sup> - Prednisolone combination therapy	546
		DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
		DOCEtaxel 50mg/m <sup>2</sup> Monotherapy-14 day	313
	Gynaecology	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
	Head & Neck	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	324
		DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	323
		DOCEtaxel (75), CISplatin (75), 5-Fluorouracil (1000), Chemoradiation and Surgery - Neoadjuvant (TCF)	315
	Lung	DOCEtaxel Monotherapy 75mg/m <sup>2</sup> – 21 day cycle	203
Nindetanib Therapy		372	
Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501	
Dostarlimab	Gynaecology	Dostarlimab Therapy	819
DOXOrubicin	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m <sup>2</sup> followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy	348
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485
		Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316

DOXOrubicin	Breast	Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin 50mg/m2/DOCEtaxel 75mg/m2(AT 50/75) Therapy - 21 day cycle	423
		DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	252
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy	734
		Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
		Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857
		858	
	Gastrointestinal	DOXOrubicin (60mg/m2) Therapy	386
	Genitourinary	Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333
		Methotrexate,Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338
	Head & Neck	Cyclophosphamide, Doxorubicin and Cisplatin Therapy - 21 Day	615
	Sarcoma	(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
		DOXOrubicin (25mg/m2/day) and CISplatin (100mg/m2) Therapy - 21 day cycle	420
		DOXOrubicin (60) and Ifosfamide Therapy	391
		DOXOrubicin (75) and Ifosfamide Therapy	392
		DOXOrubicin 75mg/m2 Monotherapy	500
		Etoposide and ifosfamide - vinCRISline, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
			747
		Ifosfamide, vinCRISline, DOXOrubicin, DACTINomycin (IVADo) Therapy	754
	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISline and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(R*)-CHOP – 21 days	307
		(R**- miniCHOP Therapy – 21 days	436
		ABVD Therapy	290
		CHOEP Therapy– 21 days	396

DOXOrubicin	Lymphoma	Dose Adjusted R-EPOCH Therapy	355
		Escalated Dose BEACOPP 21 day Therapy	354
		Nordic Therapy	393
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP) Therapy– 21 days	841
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days	667
		Dose Adjusted R (S/C)-EPOCH Therapy	672
		Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) Therapy	801
		Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE Therapy	833
Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISTine and prednisoLONE (O-CHOP) Therapy – 21 day		549	
	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496	
Myeloma	Escalated Dose BEACOPDAC 21 Day Therapy	837	
Lymphoma	Durvalumab 10mg/kg Monotherapy-14 Day	576	
	Durvalumab 1500mg Monotherapy-28 Day	655	
Durvalumab	Lung		
Encorafenib	Skin/Melanoma	Encorafenib and Binimetinib Therapy	563
Enfortumab vedotin	Genitourinary	Enfortumab vedotin Monotherapy	846
Entrectinib	Lung	Entrectinib Therapy	702
	Tumour Agnostic	Entrectinib Therapy	702
Enzalutamide	Genitourinary	Enzalutamide Monotherapy	233
epiRUBicin	Breast	5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) Therapy	265
		5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC50) Therapy	269
		epiRUBicin 75 + Cyclophosphamide (EC75) Therapy - 21 day	263
		epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	262
	Gastrointestinal	epiRUBicin, CISplatin and 5-FU (ECF) Therapy	240
		epiRUBicin, CISplatin and Capecitabine (ECX) Therapy	380
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429
epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239		
Eribulin	Breast	eriBULin Monotherapy – 28 Day	743
eriBULin	Breast	EriBULLin Monotherapy	228
	Sarcoma	EriBULLin Monotherapy	228
Erlotinib	Lung	Erlotinib Monotherapy	219
Etoposide	Genitourinary	CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen	453
		TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Gynaecology	EMA/CO Therapy	248
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
		Two Day Etoposide CISplatin (EP) Therapy	267
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264



Etoposide	Gynaecology	CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279	
	Lung	CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day	561	
		CARBOplatin (AUC5) and Etoposide 100mg/m2 Therapy-21 day	271	
		CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	456	
		CISplatin (75mg/m2) + Etoposide Therapy-21 day	280	
		Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy	689	
		CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day	279	
		Sarcoma	Ifosfamide Etoposide (IE) Therapy	596
	Lymphoma	Etoposide and ifosfamide - vinCRIStine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675	
		(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397	
		BEAM Autologous Transplant Conditioning Protocol	408	
		CHOEP Therapy– 21 days	396	
		Dose Adjusted R-EPOCH Therapy	355	
		Escalated Dose BEACOPP 21 day Therapy	354	
		LEAM Autologous Transplant Conditioning Protocol	468	
		R-CEOP Therapy – 21 days	510	
		R-IVAC Therapy (Patients greater than 65 years)	404	
		R-IVAC Therapy (Patients less than or equal to 65 years)	399	
		SMILE Therapy (NK or T-cell lymphoma)	407	
		(R*)- ESHAP Therapy	394	
		Brentuximab vedotin and ICE Therapy	528	
		Dose Adjusted R (S/C)-EPOCH Therapy	672	
		ESHAP Therapy	838	
		ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842	
		Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)	530	
		Lymphoma	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751
			Escalated Dose BEACOPDAC 21 Day Therapy	837
	Genitourinary/Gyn	Bleomycin, Etoposide and CISplatin (BEP)Therapy	300	
		Etoposide and CISplatin 20mg/m2 (EP) Therapy	301	
	Transplant	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	638	
	etoposide	Myeloma	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496
	Etoposide Oral	Lung	CARBOplatin and Oral Etoposide Therapy-21 days	319
			Oral Etoposide Therapy	388
Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy		689		
Lymphoma	R-CEOP Therapy – 21 days	510		
Everolimus	Breast	Everolimus and Exemestane Therapy	322	
	Genitourinary	Everolimus Monotherapy	320	
	Neuroendocrine	Everolimus Monotherapy	320	

Exemestane	Breast	Everolimus and Exemestane Therapy	322	
		Exemestane Monotherapy	376	
Fedratinib	Leukaemia	Fedratinib Therapy	788	
Fludarabine	Leukaemia	FLAG:Ida 8mg/m2 Therapy	362	
		Fludarabine, Cyclophosphamide and ritUXimab (FC IV+R) Therapy	241	
		Fludarabine, Cyclophosphamide and ritUXimab (FC Oral+R) Therapy	410	
		FLAG Therapy	363	
	Lymphoma (CAR-T	Lymphoma (CAR-T	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL	606
			Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®)	608
	Leukaemia (CAR-T	Transplant	Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL	607
			Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
	Folinic Acid	Gastrointestinal	Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625
			Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
			Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
			Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
			FLOT Therapy-14 day	344
			FLOX Therapy	486
FOLFIRI (14 days)+ Cetuximab (14 days) Therapy			585	
FOLFIRI (14 days)+ Cetuximab (7 days) Therapy			328	
FOLFIRI Therapy-14 day			227	
FOLFIRINOX Therapy			329	
FOLFOX-4 Therapy-14 day			210	
FOLFOXIRI Therapy			555	
Modified FOLFIRINOX Therapy			515	
Modified FOLFOX-6 Chemoradiation Therapy-14 day			509	
Modified FOLFOX-6 Therapy-14 day	209			
Modified Roswell Park (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen	427			
Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448			
Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447			
QUASAR (Modified) Fluorouracil(370mg/m2) and Folinic Acid (50mg) Weekly	428			
Roswell Park Modified (Fluorouracil 500mg/m2 and Folinic Acid 50mg weekly x 6) Regimen	427			
5-Fluorouracil and Folinic Acid Therapy-14 day	660			
FOLFIRINOX Therapy - (Rectal Carcinoma)	691			
Cetuximab and FOLFOX-4 Therapy	692			
Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704			
Cetuximab and FOLFOX-6 (modified) Therapy	733			
Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783			
Pembrolizumab and FOLFOX-6 Modified Therapy	839			
Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446			
Lymphoma	Lymphoma	R-CODOX-M Therapy (Patients greater than 65 years)	403	
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398	
		SMILE Therapy (NK or T-cell lymphoma)	407	
		ritUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664	

Fulvestrant	Breast	Fulvestrant Therapy	361	
Gefitinib	Lung	Gefitinib Monotherapy	220	
Gemcitabine	Breast	Gemcitabine and CARBOplatin (AUC2) THERAPY - 21 days	430	
		Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days	524	
	Gastrointestinal	Gemcitabine (1000mg/m2) and CISplatin (25mg/m2) Therapy- 21 day	383	
		Gemcitabine (1000mg/m2) and RT therapy	521	
		Gemcitabine (1000mg/m2) Monotherapy - 28 day	284	
		Gemcitabine (1000mg/m2) Monotherapy - 56 day	283	
		Gemcitabine (400mg/m2) and RT therapy	522	
		Gemcitabine (600mg/m2) and RT therapy	559	
		Gemcitabine + Capecitabine Therapy	384	
		Nab-PACLitaxel and Gemcitabine – 28 day	256	
		Genitourinary	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310
			Gemcitabine (1000mg/m2) and CISplatin (70mg/m2) Therapy- 28 day	282
	Gemcitabine (1000mg/m2 ) and CISplatin (35mg/m2 ) Therapy- 21 day		622	
	Gemcitabine (1000mg/m2 ) and CISplatin (70mg/m2 ) Therapy- 21 day		628	
	Gynaecology	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 4) Therapy- 21 day	306	
		Gemcitabine (1000mg/m2), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg Therapy - 21 day	499	
	Head & Neck	Gemcitabine (1250mg/m2) and CISplatin (80mg/m2) Therapy - 21 day	517	
		Gemcitabine (1250mg/m2) Monotherapy - 21 day	514	
	Lung	Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy- 21 day	310	
		Gemcitabine (1000mg/m2) Monotherapy - 28 day	284	
		Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	281	
	Sarcoma	Gemcitabine and DOCEtaxel Therapyi - 21 day	501	
	Lymphoma	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506	
riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP) (*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISline and PrednisoLONE (*R)-GCVP) Therapy–21 days		441		
			737	
	Breast	Gemcitabine (800mg/m2) Monotherapy - 28 Day	749	
Gemtuzumab ozogamicin	Leukaemia	Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction)	612	
Goserelin	Genitourinary	Goserelin 10.8mg-12 Weekly Therapy	477	
		Goserelin 3.6mg Therapy- 4 weeks	478	
Ibrutinib	Lymphoma	Ibrutinib Therapy (Mantly Cell Lymphoma)	297	
	Leukaemia	Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)	296	
Idarubicin	Leukaemia	FLAG:Ida 8mg/m2 Therapy	362	
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366	
Idelalisib	Lymphoma	Idelalisib Monotherapy	291	

Idelalisib	Leukaemia	Idelalisib and ritUXimab Therapy	389
Ifosfamide	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy	602
	Sarcoma	DOXOrubicin (60) and Ifosfamide Therapy	391
		DOXOrubicin (75) and Ifosfamide Therapy	392
		Ifosfamide Etoposide (IE) Therapy	596
		Etoposide and ifosfamide - vinCRISline, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675
			747
		High Dose Ifosfamide Therapy- 21 day	680
	Lymphoma	Ifosfamide, vinCRISline, DOXOrubicin, DACTINomycin (IVADo) Therapy	754
		(R**)-ICE ((ritUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		SMILE Therapy (NK or T-cell lymphoma)	407
		Brentuximab vedotin and ICE Therapy	528
Lymphoma	ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy	842	
	(R*)-ICE ((ritUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751	
Imatinib	Sarcoma	Imatinib Therapy-GIST	335
Inotuzumab ozogamicin	Leukaemia	Inotuzumab ozogamicin Monotherapy	537
Ipilimumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy
	Lung	Nivolumab 360mg and Ipilimumab 1mg/kg Therapy	792
		Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712
		Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713
		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714
	Skin/Melanoma	Ipilimumab Monotherapy	105
		Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431
Irinotecan	Gastrointestinal	Aflibercept-14 days	238
		Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days	449
		Cetuximab (14 days) and Irinotecan (14 days) Therapy	331
		Cetuximab (7 days) and Irinotecan (14 days) Therapy	330
		FOLFIRI (14 days)+ Cetuximab (14 days) Therapy	585
		FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	328
		FOLFIRI Therapy-14 day	227
		FOLFIRINOX Therapy	329
		FOLFOXIRI Therapy	555
		Irinotecan Monotherapy - 21 days	213
		Modified FOLFIRINOX Therapy	515
		Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Irinotecan 150mg/m2 Monotherapy - 28 days	654
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691
	Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
	Sarcoma	Irinotecan and Temozolomide Therapy- 21 days	504
		vinCRISline, Irinotecan and Temozolomide (VIT) Therapy	757
	Isotretinoin	Paediatric Oncology	Dinutuximab beta and Isotretinoin Therapy

Ixazomib	Myeloma	Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
Lapatinib	Breast	Lapatinib and Capecitabine	217
Larotrectinib	Tumour Agnostic	Larotrectinib Monotherapy - Adult	758
		Larotrectinib Monotherapy - Paediatric	P00760
L-Asparaginase	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
Lenalidomide	Myeloma	Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day	416
		Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day	516
		Lenalidomide 25mg and Dexamethasone Therapy - 28 day	218
		Carfilzomib (56mg/m <sup>2</sup> once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	598
		Carfilzomib (27mg/m <sup>2</sup> twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day	405
		Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day	643
		Bortezomib, Lenalidomide and Dexamethasone (RVD Lite) Induction Therapy	780
		Bortezomib and Lenalidomide RVD lite consolidation therapy	781
		Lenalidomide RVD lite Maintenance Therapy	782
			Myeloma
Lenvatinib	Gastrointestinal	Lenvatinib -HCC Therapy	644
Lenvatinib	Head & Neck	Lenvatinib (Lenvima) -DTC Therapy	295
Letrozole	Breast	Letrozole Monotherapy	371
Leuprorelin	Genitourinary	Leuprorelin 3.75mg Therapy-28 day	494
		Leuprorelin 30mg Therapy- 24 weeks	493
		Leuprorelin 45mg Therapy- 24 week	491
		Leuprorelin 7.5mg Therapy- 28 day	490
		Leuprorelin 11.25mg Therapy- 12 weeks	492
Leuprorelin	Genitourinary	Leuprorelin 22.5mg Therapy- 12 weeks	479
Lomustine	Neuro-oncology	Procarbazine Lomustine and VinCRiStine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRiStine (PCV) Therapy – 56 days	658
		Lomustine and Bevacizumab 5mg/kg Therapy	742
		Lomustine and Bevacizumab 7.5mg/kg Therapy	804
		Lomustine 130mg/m <sup>2</sup> Therapy	805
		CiSPlatin, Lomustine and vinCRiStine (CLV) Therapy	806
		Lymphoma	LEAM Autologous Transplant Conditioning Protocol
Lorlatinib	Lung	Lorlatinib therapy	570
Lutetium oxodotreotide	Gastrointestinal, n	Lutetium (177Lu) oxodotreotide (Lutathera®) Therapy	642
Melphalan	Lymphoma	BEAM Autologous Transplant Conditioning Protocol	408
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
		LEAM Autologous Transplant Conditioning Protocol	468
	Myeloma	Bortezomib , Melphalan and Prednisolone	275
		High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	454
	Transplant	Fludarabine/Melphalan/Alemtuzumab-RIC-SIB	611
		Fludarabine/Melphalan/Alemtuzumab-RIC-MUD	625
Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD		638	
MESNA	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
	Lymphoma	SMILE Therapy (NK or T-cell lymphoma)	407
	Lymphoma and M	Cyclophosphamide 2000mg/m <sup>2</sup> For Stem Cell Mobilisation	438

Methotrexate	Breast	Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Therapy	381
		Cylophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Therapy	378
	Genitourinary	Cylophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy	377
		CISplatin, Methotrexate and Vinblastine Therapy	337
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333
	Gynaecology	Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338
		EMA/CO Therapy	248
		Intrathecal Methotrexate for CNS Prophylaxis in GTN	249
	Sarcoma	Methotrexate 8 day Charing Cross Regimen	246
		Etoposide Methotrexate Actinomycin D/Etoposide CISplatin (EMA/EP) Therapy	264
		(MAP) Methotrexate (12000mg/m2) DOXOrubicin (37.5mg/m2/day) and CISplatin (60mg/m2) Therapy	463
	Lymphoma	VinBLAStine and Methotrexate Therapy	554
		High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		SMILE Therapy (NK or T-cell lymphoma)	407
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapy	664
	Transplant	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor	629
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor	630
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	631
		Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	635
		Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	636
		Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	637
		Busulfan/Cyclophosphamide MAC-MUD	639
		Busulfan/Cyclophosphamide MAC-SIB	641
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Sibling Donor		662	
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC –Mismatched Unrelated Donor		663	
Methylprednisolone		Lymphoma	(R*)- ESHAP Therapy
	ESHAP Therapy		838
Midostaurin	Leukaemia	Midostaurin Maintenance Therapy	661
		Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	682
		Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy	683

Mifamurtide	Sarcoma	Mifamurtide	100
mitoMYcin	Gastrointestinal	5-Fluorouracil (4 day) and mitoMYcin Chemoradiation Therapy	451
		mitoMYcin and Capecitabine Chemoradiation Therapy	727
	Genitourinary	5-Fluorouracil and mitoMYcin Chemoradiation Therapy	450
Mogamulizumab	Lymphoma	Mogamulizumab Therapy	761
nab-PACLitaxel	Breast	Atezolizumab and nab-PACLitaxel Therapy	688
		nab-PACLitaxel Weekly Monotherapy-28 day	736
	Gastrointestinal	Nab-PACLitaxel and Gemcitabine – 28 day	256
Nab-PACLitaxel (Abraxane®)	Breast	Nab-PACLitaxel (Abraxane) Monotherapy-21 day cycle	230
Neratinib	Breast	Neratinib Therapy	720
Nindetanib	Lung	Nindetanib Therapy	372
Niraparib Tablets	Gynaecology	Niraparib Tablets Monotherapy	862
Niraparib/abiraterone	Genitourinary	Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE Therapy	848
Nivolumab	Gastrointestinal	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
		Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	816
		Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	832
		Nivolumab and FOLFOX-6 Modified Therapy	844
		Nivolumab and XELOX Therapy	843
	Genitourinary	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Head & Neck	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
	Lung	Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
		Nivolumab 360mg and Ipilimumab 1mg/kg Therapy	792
		Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712
		Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713
		Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714
		Nivolumab 360mg and Chemotherapy	849
	Skin/Melanoma	Nivolumab 3mg Ipilimumab 1mg Therapy	551
		Nivolumab Monotherapy 240mg-14 day	483
		Nivolumab Monotherapy 480mg-28day	484
		Nivolumab 1mg/kg Ipilimumab 3mg/kg Therapy	431
Lymphoma	Nivolumab Monotherapy 240mg-14 day	483	
	Nivolumab Monotherapy 480mg-28day	484	
Obinutuzumab	Lymphoma	Obinutuzumab and Bendamustine Therapy-28 day cycle	424
		Obinutuzumab Maintenance Therapy -56 day	425
		Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISTine and prednisoLONE (O-CHOP) Therapy – 21 day	549
		Obinutuzumab cycloPHOSphamide vinCRISTine and prednisoLONE (O-CVP) Therapy – 21 day	550
	Leukaemia	Obinutuzumab and Chlorambucil Therapy	286
	Leukaemia	Venetoclax and obinutuzumab Therapy	715

Olaparib	Genitourinary	Olaparib (Tablet) Monotherapy	588	
	Gynaecology	Olaparib (Tablet) Monotherapy	588	
		Olaparib (Tablet) and Bevacizumab Therapy	746	
Osimertinib	Lung	Osimertinib Monotherapy	353	
Oxaliplatin	Gastrointestinal	Capecitabine/Oxaliplatin (XELOX) Therapy	321	
		epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day	429	
		epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	239	
		FLOT Therapy-14 day	344	
		FLOX Therapy	486	
		FOLFIRINOX Therapy	329	
		FOLFOX-4 Therapy-14 day	210	
		FOLFOXIRI Therapy	555	
		Modified FOLFIRINOX Therapy	515	
		Modified FOLFOX-6 Chemoradiation Therapy-14 day	509	
		Modified FOLFOX-6 Therapy-14 day	209	
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447	
		FOLFIRINOX Therapy - (Rectal Carcinoma)	691	
		Cetuximab and FOLFOX-4 Therapy	692	
		Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704	
		Cetuximab and FOLFOX-6 (modified) Therapy	733	
		Bevacizumab 5mg/kg and FOLFOXIRI Therapy -14 days	783	
		Pembrolizumab and FOLFOX-6 Modified Therapy	839	
		Nivolumab and FOLFOX-6 Modified Therapy	844	
		Bevacizumab 5mg/kg and Modified FOLFOX-6 Therapy-14 day	446	
		Nivolumab and XELOX Therapy	843	
		Lymphoma	R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506
		PACLitaxel	Breast	CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T)	278			
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)	485			
Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316			
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433			
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T)	260			
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432			
PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512			
Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507			
PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226			
PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621			
Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 Therapy	738			



PACLitaxel	Breast	Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775
		Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790
		Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle	797
		PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815
		Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
		Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857
			858
		Gastrointestinal	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks
	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day		621
	Genitourinary	TICE -Autologous Conditioning Germ Cell Tumour Regimen	437
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
	Gynaecology	PACLitaxel, Ifosfamide, and CISplatin (TIP) Therapy	602
		CARBOplatin (AUC 5-6) and Weekly PACLitaxel 80mg/m2 Therapy	308
		CARBOplatin (AUC5-7.5) and PACLitaxel 175mg/m2 Therapy	303
		PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy	266
		PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day	226
		Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m2 Therapy	620
		PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day	621
		CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	676
		Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m2	716
		Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m2 Therapy	766
		Bevacizumab 10mg/kg and PACLitaxel 80mg/m2 (day 1,8,15,22) Therapy	769
		Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy	799
Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy		811	

PACLitaxel	Gynaecology	Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817
		Lung	CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy
	Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy		579
	Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m2 Therapy		309
	PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day		226
	PACLitaxel 80mg/m2 Day 1, 8 and 15 Monotherapy-28 Day		621
	Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy	712	
Palbociclib	Breast	Palbociclib Therapy-28 day	414
Panitumumab	Gastrointestinal	Panitumumab 6mg/kg and FOLFIRI Therapy – 14 day	448
		Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy – 14 day	447
		Panitumumab 6mg/kg Therapy	225
Pazopanib	Genitourinary	Pazopanib Therapy	445
	Sarcoma	Pazopanib Therapy	445
Pegylated Liposoma	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
		Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624
		Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy	772
	Sarcoma	Pegylated Liposomal DOXOrubicin 20mg/m2 21 days	462
Pegylated Liposoma	Breast	Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
	Gynaecology	Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day	624
		Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
	Sarcoma	Pegylated Liposomal DOXOrubicin 50mg/m2 28 days	205
Pembrolizumab	Breast	Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	860
		Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	861
		Pembrolizumab, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy	857
			858
	Gastrointestinal	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy	739
		Pembrolizumab and FOLFOX-6 Modified Therapy	839
	Genitourinary	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab 200mg and Axitinib Therapy	583
	Gynaecology	Pembrolizumab 200mg Monotherapy	455
		Pembrolizumab 400mg Monotherapy	558
		Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy	811
		Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy	817
Head & Neck	Pembrolizumab 400mg Monotherapy	558	

Pembrolizumab	Head & Neck	Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy	705		
		Pembrolizumab, CISplatin and 5-Fluorouracil Therapy	706		
	Lung	Pembrolizumab 200mg Monotherapy	455		
		Pembrolizumab 400mg Monotherapy	558		
		Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy	579		
		Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568		
	Skin/Melanoma	Pembrolizumab, PEMEtrexed and CISplatin Therapy	569		
		Pembrolizumab 200mg Monotherapy	455		
	Lymphoma	Pembrolizumab 400mg Monotherapy	558		
		Pembrolizumab 400mg Monotherapy	558		
	Paediatric Oncology	Pembrolizumab Paediatric Monotherapy	P00711		
Lymphoma	Pembrolizumab 200mg Monotherapy	455			
Head and Neck	Pembrolizumab 200mg Monotherapy	455			
PEMEtrexed	Lung	Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy	568		
		Pembrolizumab, PEMEtrexed and CISplatin Therapy	569		
		PEMEtrexed and CARBOplatin Therapy	318		
		PEMEtrexed and CISplatin Therapy	317		
		PEMEtrexed Monotherapy	222		
	Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy	713			
	Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy	714			
Pertuzumab	Breast	Pertuzumab + Trastuzumab + DOCEtaxel	204		
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350		
		Pertuzumab Trastuzumab and VinORELBine	526		
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507		
		Pertuzumab and Trastuzumab Therapy	726		
		DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722		
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731		
		Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775		
		Pertuzumab/Trastuzumab	Breast	Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy	785
				DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®)(TCHP) Therapy	789
Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2)	790				
Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel Therapy - 21 day cycle	796				
Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel Therapy - 21 day cycle	797				
Pertuzumab Trastuzumab (Phesgo®) and vinORELBine	798				
Pixantrone	Lymphoma	Pixantrone Therapy	255		
Plerixafor	Lymphoma, Myeloid	Plerixafor and G-CSF Therapy	536		
Polatuzumab vedotin	Lymphoma	Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685		
		Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisolONE Therapy	833		

Pomalidomide	Myeloma	Pomalidomide and Dexamethasone	245
Pomalidomide	Myeloma	Pomalidomide, Bortezomib and Dexamethasone (PVD) Therapy	601
Ponatinib	Leukaemia	Ponatinib Therapy	302
prednisoLONE	Genitourinary	Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE Therapy	848
Procarbazine	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379
		Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	658
	Lymphoma	Escalated Dose BEACOPP 21 day Therapy	354
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664
Radium 223	Genitourinary	Radium 223 Therapy	257
Regorafenib	Gastrointestinal	Regorafenib Monotherapy	244
Relugolix	Genitourinary	Relugolix Therapy	830
Ribociclib	Breast	Ribociclib Therapy-28 day	525
riTUXimab	Lymphoma	(*riTUXimab) Cyclophosphamide, DOXOrubicin,vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409
		(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293
		(R*)-CHOP – 21 days	307
		(R**)- miniCHOP Therapy – 21 days	436
		(R**)-DHAP Therapy	395
		(R**)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy	397
		Dexamethasone, riTUXimab and Cyclophosphamide (DRC)Therapy	532
		Dose Adjusted R-EPOCH Therapy	355
		High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
		Nordic Therapy	393
		R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		R-Gemcitabine (1000mg/m2) Oxaliplatin Therapyi - 14 day	506
		riTUXimab 375 mg/m2 Combination Therapy-21 day	542
		RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day	543
		RiTUXimab 375 mg/m2 Maintenance Therapy-84 day	540
		RiTUXimab 375 mg/m2 Therapy-7 day	541
		riTUXimab and Bendamustine Therapy	345
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		R-IVAC Therapy (Patients greater than 65 years)	404
		R-IVAC Therapy (Patients less than or equal to 65 years)	399
		riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B	467
		(R*)- ESHAP Therapy	394
		riTUXimab* Gemcitabine, Dexamethasone and CISplatin ((R**)-GDP)	441
		RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day	599
		RiTUXimab (S/C 1400mg) Maintenance Therapy-56 day	600
		riTUXimab, Methotrexate, Procarbazine and vinCRISTine (R-MPV) – 14 Days Induction Therapyi	664

riTUXimab	Lymphoma	riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days	667
		Dose Adjusted R (S/C)-EPOCH Therapy	672
		Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy	685
		(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISTine and PrednisoLONE (*R)-GCVP) Therapy–21 days	737
		Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE Therapy	833
	Leukaemia	Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) Therapy	241
		Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy	410
		Idelalisib and riTUXimab Therapy	389
		Venetoclax and Rituximab therapy	575
	Lymphoma	(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient	751
Leukaemia, Lymph	Cladribine 5 day and riTUXimab Therapy	531	
	Cladribine Weekly and riTUXimab Therapy	534	
Ruxolitinib	Leukaemia	Ruxolitinib Monotherapy	229
Sacituzumab Govitec	Breast	Sacituzumab Govitecan Therapy	794
Siltuximab	Lymphoma	Siltuximab Monotherapy	277
Sorafenib	Gastrointestinal	Sorafenib Therapy	294
	Genitourinary	Sorafenib Therapy	294
	Head & Neck	Sorafenib Therapy	294
Sunitinib	Genitourinary	SUNitinib 50mg Therapy (21 days)	719
	Sarcoma	SUNitinib 50mg Therapy (21 days)	719
Sunitinib	Genitourinary	Sunitinib 50mg Therapy	325
	Sarcoma	Sunitnib 50mg Therapy	325
	Neuroendocrine	Sunitnib 37.5mg Therapy	327
Talazoparib	Breast	Talazoparib Therapy	605
Tamoxifen	Breast	Tamoxifen Monotherapy	253
Temozolomide	Gastrointestinal	Capecitabine and Temozolomide Therapy*	505
	Sarcoma	Irinotecan and Temozolomide Therapy- 21 daysi	504
	Neuro-oncology	Temozolomide Recurrent Therapy	342
		Temozolomide with Radiotherapy (RT) and Adjuvant Therapy- Patients greater than 65 years	461
		Temozolomide with RT and Adjuvant Therapy	334
temozolomide	Sarcoma	vinCRISTine, Irinotecan and Temozolomide (VIT) Therapyi	757
Temsirolimus	Genitourinary	Temsirolimus Monotherapy	326
Tepotinib	Lung	Tepotinib Therapy	823
Teysuno	Gastrointestinal	CISplatin and Teysuno-28 day cycle	235
Thalidomide	Myeloma	Bortezomib + Dexamethasone +Thalidomide (VTD)Induction Therapy	274
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy	703
			752
		Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy	755
			756

Thalidomide	Myeloma	Bortezomib, dexAMETHasone, Thalidomide, CISplatin, DOXOrubicin, cycloPHOSphamide and Etoposide (VDT PACE) Therapy	496
Thiotepa	Lymphoma	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	508
Tisagenlecleucel	Leukaemia (CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) B-ALL	686
	Lymphoma (CAR-T	Tisagenlecleucel (Kymriah®) (CAR-T) DLBCL	687
Tivozanib	Genitourinary	Tivozanib Therapy	564
Topotecan	Gynaecology	Topotecan Monotherapy-5 day	311
		Topotecan Monotherapy-Weekly	312
		Bevacizumab 10mg/kg and Topotecan 4mg/m2 therapy	771
	Lung	Topotecan Monotherapy-5 day	311
		Topotecan Oral Monotherapy	587
Trabectedin	Gynaecology	Trabectedin and Pegylated Liposomal DOXOrubicin(PLD) Therapy	375
	Sarcoma	Trabectedin Monotherapy	374
Trametinib	Skin/Melanoma	Trametinib and Dabrafenib Therapy	415
Trastuzumab	Breast	Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2)	775
	Gastrointestinal	Trastuzumab and FOLFOX-6 Modified Therapy-14 day	704
Trastuzumab	Breast	PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815
Trastuzumab derux	Breast	Trastuzumab Deruxtecan (Enhertu®) Therapy	776
Trastuzumab emtan	Breast	Trastuzumab Emtansine (Kadcyla® ) Early Breast Cancer Therapy- 21 days	659
Trastuzumab Emtansine (Kadcyla®)	Breast	Trastuzumab Emtansine (Kadcyla®) - 21 days	206
Trastuzumab IV	Breast	Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH)	316
		Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	433
		DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)	432
		PACLitaxel (80) and Trastuzumab Therapy – 7 day (12 weeks)	512
		Pertuzumab + Trastuzumab + DOCETaxel	204
		pertuzumab and trastuzumab and chemotherapy -21 day cycles	350
		Pertuzumab Trastuzumab and VinORELBine	526
		Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle	507
		Trastuzumab (IV) Monotherapy 21 days	200
		Trastuzumab (IV) Monotherapy 7 days	201
Pertuzumab and Trastuzumab Therapy	726		
		Dose Dense Doxorubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and Trastuzumab 21 day Therapy (DD AC-TH)	745
	Gastrointestinal	Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days	502
Trastuzumab SC	Breast	Trastuzumab SC 21 days-Early Breast Cancer	285

Trastuzumab SC	Breast	Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma	272	
		PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy	815	
Trastuzumab	Breast	DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	258	
Trastuzumab IV	Breast	DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy	722	
		DOCEtaxel, CARBOplatin, Trastuzumab(S/C) and Pertuzumab (TCHP) Therapy	731	
Tretinoin (ATRA)	Leukaemia	Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy	357	
		Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy	356	
		Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy	366	
Trifluridine and Tipiracil	Gastrointestinal	Trifluridine and Tipiracil (Lonsurf®) Therapy	382	
Triptorelin	Genitourinary	Triptorelin 11.25mg Therapy- 12 weeks	480	
		Triptorelin 22.6mg Therapy- 24 weeks	488	
		Triptorelin 3mg Therapy- 28 day	489	
Vandetanib	Head & Neck	Vandetanib Monotherapy	242	
Vemurafenib	Skin/Melanoma	Cobimetinib and Vemurafenib Therapy	373	
		Vemurafenib Monotherapy	102	
Venetoclax	Leukaemia	Venetoclax Monotherapy	400	
Venetoclax	Leukaemia	Venetoclax and obinutuzumab Therapy	715	
	Leukaemia	Venetoclax and azaCITIDine Therapy	852	
Venetoclax	Leukaemia	Venetoclax and Rituximab therapy	575	
Vinblastine	Genitourinary	CISplatin, Methotrexate and Vinblastine Therapy	337	
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 14 Days Therapy	333	
		Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy- 28 Days	338	
	Sarcoma	VinBLASTine and Methotrexate Therapy	554	
	Lymphoma	ABVD Therapy	290	
VinCRISTine	Gynaecology	EMA/CO Therapy	248	
	Sarcoma	Etoposide and ifosfamide - vinCRISTine, DOXOrubicin and cyclophosphamide (IE-VAC) Therapy – Two Weekly Intervals	675	
				747
		Ifosfamide, vinCRISTine, DOXOrubicin, DACTINomycin (IVADo) Therapy	754	
		vinCRISTine, Irinotecan and Temozolomide (VIT) Therapy	757	
	Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy	379	
		Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	658	
		CISplatin, Lomustine and vinCRISTine (CLV) Therapy	806	
	Lymphoma	(**riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	409	
		(*riTUXimab), Cyclophosphamide VinCRISTine and Prednisolone (*R)-CVP) Therapy– 21 days	293	
		(R*)-CHOP – 21 days	307	
		(R**) - miniCHOP Therapy – 21 days	436	
		CHOEP Therapy– 21 days	396	
Dose Adjusted R-EPOCH Therapy		355		
Escalated Dose BEACOPP 21 day Therapy		354		
Nordic Therapy	393			

VinCRISStine	Lymphoma	R-CEOP Therapy – 21 days	510
		R-CODOX-M Therapy (Patients greater than 65 years)	403
		R-CODOX-M Therapy (Patients less than or equal to 65 years)	398
		riTUXimab-HyperCVAD Therapy (MCL) – Part A	466
		Cyclophosphamide, DOXOrubicin, vinCRISStine and prednisoLONE (CHOP) Therapy– 21 days	841
		riTUXimab, Methotrexate, Procarbazine and vinCRISStine (R-MPV) – 14 Days Induction Therapy	664
		riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISStine and Prednisolone (R-CHOP) Therapy– 21 Days	667
		Dose Adjusted R (S/C)-EPOCH Therapy (*riTUXimab)-Gemcitabine Cyclophosphamide vinCRISStine and PrednisoLONE (*R)-GCVP) Therapy–21 days	737
		Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRISStine and prednisoLONE (O-CHOP) Therapy – 21 day	549
		Obinutuzumab cycloPHOSphamide vinCRISStine and prednisoLONE (O-CVP) Therapy – 21 day	550
	Lymphoma	Escalated Dose BEACOPDAC 21 Day Therapy	837
Vinorelbine	Breast	Pertuzumab Trastuzumab (Phesgo®) and vinORELbine	798
	Lung	CARBOplatin and vinORELbine Therapy-21 Day	614
Vinorelbine IV	Breast	Intravenous Vinorelbine Monotherapy-21day	232
		Pertuzumab Trastuzumab and VinORELbine	526
	Gynaecology	Intravenous Vinorelbine Monotherapy-21day	232
	Lung	Intravenous Vinorelbine Monotherapy-21day	232
		Vinorelbine and CISplatin Therapy-21 days	339
	Vinorelbine and CISplatin Therapy-28 days	343	
Vinorelbine Oral	Breast	Oral Vinorelbine Monotherapy-7days	259
	Lung	Oral Vinorelbine Monotherapy-7days	259
Vismodegib	Skin/Melanoma	Vismodegib Monotherapy	236
Vyxeos liposomal®	Leukaemia	Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction Therapy	613
		Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation Therapy	618
Zanubrutinib	Lymphoma	Zanubrutinib Therapy	708
Zoledronic acid	Breast	Zoledronic acid monotherapy	545
	Breast, Genitourin	Zoledronic Acid Therapy-28 days	723
		Zoledronic Acid Therapy-3 monthly	724
		Zoledronic Acid Therapy-6 monthly	725